Analyzing the Future of Exocrine Pancreatic Insufficiency Market Dynamics 2025-2034: Growth Rate, Trends, and Major Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the Exocrine Pancreatic Insufficiency market grown in recent years?
Over the recent years, the exocrine pancreatic insufficiency market size has seen robust growth. Its expansion will continue from $2.59 billion in 2024 to $2.76 billion in 2025, with a compound annual growth rate (CAGR) of 6.6%. The past growth spurt can be linked to increased understanding and diagnosis, a surge in digestive disorders, an aging populace, a decrease in pancreatic function, and an increase in gastrointestinal surgeries.
How is the exocrine pancreatic insufficiency market size expected to evolve during the forecast period?
The market size for exocrine pancreatic insufficiency is set to experience substantial expansion in the forthcoming years, scaling to $3.58 billion by 2029, at a compound annual growth rate (CAGR) of 6.7%. Factors contributing to this projected growth during the forecast period include an ongoing rise in awareness and screening, an increasing elderly population, a higher incidence of chronic diseases, enhanced access to healthcare for patients, as well as research and development actions in the area of digestive health. Other significant trends for the forecast period comprise digital health and telehealth solutions, synergistic research efforts, increased concentration on pediatric epi, advances in regulatory processes and accelerated track designations, market proliferation in emerging nations and breakthroughs in healthcare infrastructure.
Get your exocrine pancreatic insufficiency market report here!
Which key drivers are propelling the exocrine pancreatic insufficiency market’s growth?
The escalating trend of chronic diseases is speculated to accelerate the exocrine pancreatic insufficiency market’s expansion. Chronic diseases, medical conditions that persist for three months or longer, gradually increase the patient’s risk of developing secondary complications, including exocrine pancreatic insufficiency. This heightens the need for effective management of chronic diseases through medical treatments and therapies potentially contributing to extended lifespans. A case in point, the World Health Organization, located in Switzerland, reported in September 2023 that annually 41 million people die globally, 74% of which are due to non-communicable diseases (NCDs) or chronic diseases. Hence, the surge in chronic diseases signifies an upward trajectory for the exocrine pancreatic insufficiency market.
Exocrine Pancreatic Insufficiency Market Trigger: Burgeoning Diabetes Epidemic Stimulating The Growth Of The Exocrine Pancreatic Insufficiency Market
What are the market segments in the exocrine pancreatic insufficiency industry?
The exocrine pancreatic insufficiency market covered in this report is segmented –
1) By Treatment: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Other Treatments
2) By Diagnosis: Imaging Tests, Computed Tomography (CT) Scan, Abdominal Ultrasound, Secretin Pancreatic Function Test, Fecal Fat Test, Fecal Elastase Test (FE-1), Other Types
3) By Symptoms: Abdominal Pain, Constipation, Diarrhea, Fatty Stools, Weight Loss, Other Symptoms
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End Users: Hospitals, Specialty Clinics, Homecare
Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Enteric-Coated Capsules, Non-Enteric-Coated Capsules, Powder Formulations
3) By Other Treatments: Medications, Surgical Interventions, Supportive Therapies
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13107&type=smp
Which leading companies are shaping the growth of the exocrine pancreatic insufficiency market?
Major companies operating in the exocrine pancreatic insufficiency market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Nestle Health Science S.A., Allergan PLC, Chiesi Farmaceutici S.p.A., Wockhardt Ltd., Amryt Pharma PLC, Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, Aimmune Therapeutics Inc., Digestive Care Inc., Enzymedica Inc., Vivus Inc., Alcresta Therapeutics Inc., Cilian AG, Perseo Pharma AG, Enzyme Development Corporation, First Wave BioPharma Inc., Synspira Therapeutics
What key trends are currently impacting the exocrine pancreatic insufficiency market’s development?
Leading businesses in the exocrine pancreatic insufficiency market are prioritizing the formation of patient support groups, like comprehensive nutritional guidance, to provide extensive nutritional advice and backing. These steps are taken to enhance awareness, education, and control of the condition among those afflicted. Comprehensive nutritional guidance is an all-encompassing approach that customizes dietary suggestions according to personal needs, health scenarios, and lifestyle. It stresses on learning, meal preparation, and enduring habits to boost general well-being. For example, in June 2024, Nestlé Health Science, a nutrition firm based in Switzerland, introduced a GLP-1 nutrition support platform. Nestlé Health Science’s GLP-1 nutrition support platform presents personalized nutritional tools and professional advice for individuals on GLP-1 medications, with a focus on muscle sustenance, gut health, and complete wellness. The aim is to strengthen users in their weight control journey by meeting specific dietary requirements and encouraging communal support.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13107
Which geographic areas are influencing the growth of the exocrine pancreatic insufficiency market?
North America was the largest region in the exocrine pancreatic insufficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exocrine pancreatic insufficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Mineral And Bone Disorder Treatment Global Market Report 2024
Acute Spinal Cord Injury Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/acute-spinal-cord-injury-global-market-report
Acute Pancreatitis Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
